Navigation Links
AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China
Date:5/27/2008

SHENYANG, China, May 28 /Xinhua-PRNewswire-FirstCall/ -- AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG) and 3SBio, Inc. (Nasdaq: SSRX), a leading Chinese biotechnology company, today announced the signing of a development and commercialization agreement for ferumoxytol, an intravenous iron replacement therapeutic agent being developed to treat iron deficiency anemia in chronic kidney disease (CKD) patients.

"This is an exciting first step towards expanding the potential use of ferumoxytol outside the United States. China represents a large and rapidly growing market opportunity as there are approximately 12 million Stage 3 and 4 CKD patients(1), and over 91,000 patients on dialysis in China(2)," stated Brian J.G. Pereira, MD, President and CEO of AMAG Pharmaceuticals, Inc., "With their leading position in the nephrology therapeutic market, nationwide specialty sales force, and strong marketing capabilities, 3SBio is an ideal partner to develop and commercialize ferumoxytol in China."

Under the terms of the agreement, AMAG will grant 3SBio exclusive rights to develop and commercialize ferumoxytol in China, initially for CKD, and with an option to expand into additional indications. 3SBio will be responsible for the clinical development, registration, and commercialization of ferumoxytol in China. AMAG and 3SBio will form a joint steering committee, with equal representation from both parties, to oversee and guide the development and commercialization of ferumoxytol in China. The agreement has an initial duration of thirteen years and will be automatically renewed for a set term if minimum sales thresholds are achieved. AMAG will retain all manufacturing rights for ferumoxytol and will provide, under a separate agreement, commercial supply to 3SBio at a predetermined supply price.

AMAG will receive an upfront payment of $1 million from 3SBio and is eligible to receive additional milestone payments upon regulatory approval of ferumoxytol in China for CKD and other specified indications. AMAG is also entitled to receive tiered, double-digit royalties, of up to 25%, based on sales of ferumoxytol by 3SBio.

"We are very pleased that AMAG Pharmaceuticals has entrusted 3SBio to develop and commercialize ferumoxytol in China," said Dr. Jing Lou, Chief Executive Officer of 3SBio. "Along with AMAG, we are committed to bringing this innovative medicine to millions of patients in China. This partnership represents a key milestone towards our goal of establishing 3SBio as the partner of choice in China for biotechnology companies around the world."

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.

Ferumoxytol, the Company's key product candidate, is being developed for use as an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in chronic kidney disease patients. The Company has released data on all four planned Phase III clinical trials of ferumoxytol as an intravenous iron replacement therapeutic agent in chronic kidney disease patients. The Company submitted a New Drug Application for marketing approval of ferumoxytol with the U.S. Food and Drug Administration (FDA) in December 2007, which was accepted for filing by the FDA in February 2008.

About 3SBio, Inc.

3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. The Company's corporate headquarters and manufacturing facilities are located in Shenyang with sales headquarters in Beijing.

(1) Kidney International, (2005) 68; 2837-2845

(2) Nephrology Dialysis Transplantation (2005) 20: 2587-2593

For more information, please contact:

AMAG Pharmaceuticals, Inc.

Kristen Galfetti

Tel: +1-617-498-3362

Email: kgalfetti@amagpharma.com

3SBio, Inc.

Mahmoud Siddig

Tel: +1-212-889-4350

Email: 3Sbio@taylor-rafferty.com


'/>"/>
SOURCE 3SBio, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
2. Medimetriks Pharmaceuticals, Inc. Begins Operations
3. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
4. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
6. Jazz Pharmaceuticals, Inc. to Announce First Quarter Results on May 13, 2008
7. Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing
8. Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition
9. GlaxoSmithKline to Acquire Sirtris Pharmaceuticals, a World Leader in Sirtuin Research and Development
10. Pacira Pharmaceuticals, Inc. Expands Development Collaborations for DepoFoam(R)
11. Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
(Date:6/23/2016)... Francisco, CA (PRWEB) , ... June 23, 2016 ... ... (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase its ... Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical ...
(Date:6/23/2016)... , June 22, 2016  Amgen (NASDAQ: ... of the QB3@953 life sciences incubator to ... health. The shared laboratory space at QB3@953 was created ... a key obstacle for many early stage organizations - ... of the sponsorship, Amgen launched two "Amgen Golden Ticket" ...
(Date:6/22/2016)... 22, 2016 Research and Markets has announced ... report to their offering. ... from $29.3 billion in 2013. The market is expected to grow ... 2015 to 2020, increasing from $50.6 billion in 2015 to $96.6 ... during the forecast period (2015 to 2020) are discussed. As well, ...
Breaking Biology Technology:
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
(Date:3/31/2016)... RATON, Florida , March 31, 2016 ... LEGX ) ("LegacyXChange" or the "Company") ... for potential users of its soon to be launched ... video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide ... the use of DNA technology to an industry that ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):